Alteogen reports 1Q26 consolidated revenue KRW71.6bn, operating profit KRW39.3bn; strong global licensing deals

1Q26 consolidated results: Revenue KRW71,599M, Operating profit KRW39,301M, Net income KRW71,344M (attributable to parent KRW71,697M)
ALT-B4 licensing deals: MSD (up to US$4.317B+royalty, Keytruda SC FDA/EU approval achieved), AstraZeneca (MedImmune, US$1.35B), GSK (Tesaro, US$285M), Daiichi Sankyo (US$300M), Biogen (US$579M); milestone payments received
Key pipelines: ALT-L9 (Eylea biosimilar) received EMA marketing authorization; domestic approval filed; ALT-BB4 (Tergase) domestic approval in 2024; ALT-L2 (Herceptin biosimilar) selling in China
Financial health: Debt ratio 42.2% (improved from 53.7% at year-end 2025), net debt KRW125.6B, total borrowings KRW167.9B vs cash equivalents KRW42.3B
Dividend: First dividend paid in FY2025 (KRW1,000 per share, resolved at AGM); articles amended to allow quarterly dividends